Copyright thehindubusinessline
Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Alkem Laboratories Ltd is collaborating with the Indian Institute of Technology Bombay to set up a research centre in India for immuno-therapeutics and regenerative medicines. Alkem Foundation will invest ₹77 crore for starters in setting-up the centre in the IIT Bombay campus, a person familiar with the development told businessline. This centre looks to foster research and innovation in complex disease areas, that have an unmet medical needs and Alkem Foundation will contribute 20-25 percent of its cumulative CSR obligations over seven years on this research centre, it said. This project is the first industry-academia collaboration in the country, through CSR, for advancing research in the areas of immuno-therapeutics and regenerative medicines, it said. “The partnership brings together Alkem’s pharmaceutical industry insights and experience in developing healthcare solutions, and IIT Bombay’s expertise in biomedical engineering, biosciences, and translational research, along with a pool of globally trained faculty, to create a distinctive innovation and translation ecosystem,” it explained. The initiative will augment IIT Bombay’s multidisciplinary approach to healthcare integrating biology, engineering, and data science to advance human health, it added. The Institute’s research covers biotechnology, biomedical engineering, and cell and gene therapy. The new research centre will expand into emerging areas such as gene editing and biomaterials, besides training and acting as an incubation hub for clinician-scientists and biotech entrepreneurs, strengthening India’s translational research ecosystem in life sciences, it added. Madhurima Singh, Alkem’s Executive Director and Chairperson of the CSR and Sustainability Committee, said, “Despite government encouragement, only a small share of corporate CSR spending in India goes towards R&D (research and development). We saw it as our responsibility to go beyond business and support R&D in the important field of immuno-therapeutics and regenerative medicines through CSR.” Shireesh B. Kedare, Director, IIT Bombay, said, “IIT Bombay’s strong foundation in biotechnology, biomedical engineering, and regenerative sciences positions us to translate cutting-edge research into real-world healthcare impact. This collaboration will foster clinical breakthroughs that lead to affordable therapies, reduce dependence on imports, and take us a step further in India’s journey toward self-reliance in healthcare innovation.” Published on November 3, 2025
